Provided by Tiger Trade Technology Pte. Ltd.

ASCENTAGE

30.740
+0.3801.25%
Volume:2.83M
Turnover:86.25M
Market Cap:11.50B
PE:-8.81
High:31.040
Open:30.000
Low:29.740
Close:30.360
52wk High:79.300
52wk Low:28.200
Shares:374.00M
HK Float Shares:374.00M
Volume Ratio:1.13
T/O Rate:0.76%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-3.490
ROE:-236.63%
ROA:-28.04%
PB:17.67
PE(LYR):-8.81
PS:15.30

Loading ...

Ascentage Pharma Group International's Chairman Buys 38,630 Shares

Reuters
·
Sep 28

Ascentage Pharma Group International - Chairman Buys 38,630 Shares for Hk$1.2 Mln at Hk$29.95 Per Share on Sept 23-25

THOMSON REUTERS
·
Sep 28

Ascentage Pharma: Trustee Acquires 50,000 Shares to Fund 2022 RSU Scheme Vesting

Bulletin Express
·
Sep 28

Ascentage Pharma Trustee Acquires 50,000 Shares for 2022 Restricted Share Unit Scheme

Stock News
·
Sep 17

ASCENTAGE H1 2026: Revenue Climbs 29.3 % to RMB 302.20 Million; Net Loss Deepens on R&D and Commercial Scale-Up

Bulletin Express
·
Sep 17

Movement Alert|ASCENTAGE Falls 5.21% in Regular Trading, Biotech Sector Continues to Weaken Amid Widening Net Loss and ATM Offering Overhang

Market Focus
·
Sep 11

Movement Alert|ASCENTAGE Falls 5.09% in Regular Trading, Trading at HK$32.46

Market Focus
·
Sep 10

Movement Alert|ASCENTAGE Rises 5.02% in Regular Trading, World CLL Day Catalyst Combined with CICC Maintaining Outperform Rating

Market Focus
·
Sep 03

Movement Alert|ASCENTAGE Falls 5.2% in Regular Trading, Trading at HK$34.96

Market Focus
·
Aug 28

Movement Alert|ASCENTAGE Intraday Rise 13.18%, H1 Revenue Growth and Broker Initiation Drive Rally

Market Focus
·
Aug 27

What Does The Future Hold For Ascentage Pharma Group International (HKG:6855)? These Analysts Have Been Cutting Their Estimates

Simply Wall St.
·
Aug 25

China's Henlius H1 Revenue Jumps on Drug Sales, License Income

Reuters
·
Aug 21

Biotech Firm Antengene's H1 Revenue Jumps on Licensing Deals

Reuters
·
Aug 21

China's Brii Biosciences Interim Net Loss Narrows on Lower R&D Expenses

Reuters
·
Aug 21

Ascentage Pharma Appoints Faiçal Miyara Chief Business Officer, Names Jim Ziegler Chief Commercial Officer

Reuters
·
Aug 20

Ascentage Pharma Posts Interim Results Presentation on 1H 2026 Business Update

Reuters
·
Aug 20

Ascentage Pharma Reports 2026 Interim Results: Strengthening Commercial Engine and Accelerating Global Expansion

Stock News
·
Aug 20

Ascentage Pharma Group International Posts H1 Net Loss Attributable Rmb816.7 Million

Reuters
·
Aug 20

China's Ascentage Pharma H1 Revenue Rises 29% on Lisaftoclax Ramp-up

Reuters
·
Aug 20

Ascentage Pharma Group International H1 Revenue RMB 302.2 Million

THOMSON REUTERS
·
Aug 20